Drug Profile


Alternative Names: A-195773; A-195773-0; Abbott-195773; ABT 773; Restanza

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Advanced Life Sciences; National Institute of Allergy and Infectious Diseases; Taisho Pharmaceutical; United States Army Medical Research Institute of Infectious Diseases; Walter Reed Army Institute of Research
  • Class Antibacterials; Ketolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Plague; Tularaemia; Anthrax
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Anthrax; Community-acquired pneumonia; Gonorrhoea; Malaria; Melioidosis; Plague; Tularaemia
  • No development reported Acute sinusitis; Clostridium infections
  • Discontinued Bacterial infections; Toxoplasmosis

Most Recent Events

  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Canada (PO)
  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Europe (PO)
  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top